A report yesterday on on the MedPage Today web site quotes Scott Gottlieb, MD, the Commissioner of the U.S. Food & Drug Administration (FDA) on the importance of “Listening to patients” and on how patients’ perspectives can inform drug development, drug review, and physicians’ prescribing habits. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: development, drug, opinion, patient, regulation | 1 Comment »
Readers with an interest in how we got to today’s clinical trials processes for evaluating new drugs for the treatment of prostate cancer and other diseases might be surprised by what’s in an article in this week’s New England Journal of Medicine. … READ MORE …
Filed under: Drugs in development | Tagged: development, drug, marketing, regulation, trials | 2 Comments »
There are a lot of media reports today about a protein called Bmi-1 and its impact on the regulation and development of prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: Bmi-1, cell, growth, regulation | 2 Comments »
A new paper by Wang et al. in a recent issue of Cancer Research has proposed details of a specific connection between control over the growth and division of prostate cancer cells and clinical occurrence of the more aggressive forms of prostate cancer. … READ MORE …
Filed under: Management, Risk | Tagged: aggressive, cell, indolent, messenger RNA, microRNA, regulation | 3 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 